993 results on '"BACH, PETER B."'
Search Results
2. Compulsory Licensing of Pharmaceuticals in High-Income Countries : A Comparative Analysis
3. Reply to: Limitations of molecular testing in combination with computerized tomographic for lung cancer screening
4. Trends in financial payments from industry to US cancer centers, 2014-2021.
5. The Prescription Drug User Fee Act: Much More Than User Fees
6. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer
7. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
8. Cell-free DNA approaches for cancer early detection and interception
9. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
10. The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating
11. An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries
12. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
13. Abstract CT068: CASCADE-LUNG: validation of a blood-based assay that evaluates cell-free DNA fragmentation patterns to detect lung cancer
14. Abstract 5766: Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection
15. Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population
16. Identifying and Measuring Hospital Characteristics Using the SEER-Medicare Data and Other Claims-Based Sources
17. Patient Demographic and Socioeconomic Characteristics in the SEER-Medicare Database: Applications and Limitations
18. Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer
19. Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer
20. INCORPORATING CLINICAL RISK INTO BIOMARKER-BASED ASSESSMENT USED AS PRESCREENING PRIOR TO LOW-DOSE CT LUNG CANCER SCREENING
21. Provider Differences in Use of Implanted Ports in Older Adults With Cancer
22. Pricing in the Market for Anticancer Drugs
23. Late-Stage Cancer End Points to Speed Cancer Screening Clinical Trials—Not So Fast.
24. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
25. Industry Payments to Physicians Are Kickbacks. How Should Stakeholders Respond?
26. Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
27. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug
28. Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric Adenocarcinoma
29. Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation
30. Despite The FDA’s Five-Year Plan, Black Patients Remain Inadequately Represented In Clinical Trials For Drugs
31. The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide: Results from a Prospective Randomized Trial
32. Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
33. Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014–2017
34. A Decade of Mortality Reductions in Major Oncologic Surgery: The Impact of Centralization and Quality Improvement
35. Geographic Access and the Use of Screening Mammography
36. Do Surgical Quality Gaps Cause Healthcare Disparities?
37. Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics
38. Mapping conflict of interests: scoping review
39. Fragmentation of Care for Frequently Hospitalized Urban Residents
40. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
41. Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
42. Racial Disparities and Site of Care
43. Overspending driven by oversized single dose vials of cancer drugs
44. How to Help Lower Drug Costs
45. The Drugs at the Heart of Our Pricing Crisis
46. Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs
47. Comorbidities, Smoking Status, and Life Expectancy Among Individuals Eligible for Lung Cancer Screening
48. Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage
49. New Math on Drug Cost-Effectiveness
50. Impact of Infection by Vancomycin‐Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.